Abstract
Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclooxygenase-2.
Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of meloxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies.
Neither moderate renal nor hepatic insufficiency significantly alter the pharmacokinetics of meloxicam. Dosage adjustment is not required in the elderly. Drug-drug interaction studies are available for some commonly co-prescribed medications. Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for this NSAID.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44 (10): 423–33.
Luger P, Daneck K, Engel W, et al. Structure and physiochemical properties of meloxicam, a new NSATD. Eur J Pharm Sci 1996; 4 (3): 175–87.
Albengres E, Urien S, Barre J, et al. Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity. Int J Tissue React 1993; 15 (3): 125–34.
Roszko P. Meloxicam: a COX-2 preferential NSATD. TBC’s Industry Symposium on COX-2 Inhibitors. Applications in Inflammation, Cancer, and Alzheimer’s Disease: 1998 Aug 6–7; San Diego. In press.
Noble S, Balfour JA. Meloxicam. Drugs 1996; 51 (3): 424–30; discussion 431–32.
Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35 Suppl. 1: 13–6.
Türck D, Busch U, Heinzel G, et al. Basic clinical pharmacokinetics of meloxicam, a new NSAID [abstract]. Scand J Rheumatol 1994; S98: A120.
Türck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxicam. Arzneimittel Forschung 1997; 47 (3): 253–8.
Busch U, Heinzel G, Narjes H. Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agents Actions 1991; 32 (1–2): 52–3.
Narjes H, Türck D, Busch U, et al. Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br J Clin Pharmacol 1996; 41 (2): 135–9.
Schmid J, Busch U, Heinzel G, et al. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 1995; 23 (11): 1206–13.
Degner F, Heinzl G, Busch U. Transsynovial kinetics of meloxicam [abstract]. Scand J Rheumatol 1994; S98: A121.
Jolliet P, Simon N, Bree F, et al. Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery. Pharm Res 1997; 14 (5): 650–6.
Chesne C, Guyomard C, Guillouzo A, et al. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998; 28 (1): 1–13.
Auvinet B, Ziller R, Appelboom T, et al. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin Ther 1995; 17 (6): 1078–98.
Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33 (3): 184–213.
Engelhardt G, Trummlitz G. Biological activity of the main metabolites of meloxicam. Drugs Exp Clin Res 1990; 16 (2): 53–6.
Sander O, Hübner G, Türck D, et al. Meloxicam pharmacokinetics in elderly compared to younger male and female patients with rheumatoid arthritis. Rheumatol Eur 1995; 24 (S3): 221.
Boulton-Jones JM, Geddes CG, Heinzel G, et al. Meloxicam pharmacokinetics in renal impairment. Br J Clin Pharmacol 1997; 43 (1): 35–40.
Bevis PJ, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 1996; 35 Suppl. 1: 56–60.
Türck D, Schwarz A, Hoffler D, et al. Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. Eur J Clin Pharmacol 1996; 51 (3–4): 309–13.
Busch U, Heinzel G, Narjes H, et al. Pharmacokinetics of meloxicam in patients with liver insufficiency associated with liver cirrhosis. Rheumatol Eur 1995; 24 (S3): 177.
Türck D, Su CA, Heinzel G, et al. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997; 51 (5): 421–5.
Degner FL, Heinzel G, Narjes H, et al. The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin. Br J Clin Pharmacol 1995; 40 (5): 486–8.
Muller FO, Schall R, de Vaal AC, et al. Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur J Clin Pharmacol 1995; 48 (3–4): 247–51.
Müller FO, Middle MV, Schall R, et al. An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure. Br J Clin Pharmacol 1997; 44 (4): 393–8.
Hubner G, Sander O, Degner FL, et al. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol 1997; 24 (5): 845–51.
Busch U, Heinzel G, Narjes H, et al. Interaction of meloxicam with Cimetidine, Maalox, or aspirin. J Clin Pharmacol 1996; 36 (1): 79–84.
Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal antiinflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995; 48 (3–4): 269–72.
Pairet M, van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res 1998; 47 Suppl. 2: S93–101.
Pairet M, van Ryn J, Schierok H, et al. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 1998; 47 (6): 270–6.
Forsyth SF, Guilford WG, Haslett SJ, et al. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. J Small Anim Pract 1998; 39 (9): 421–4.
Lipscomb GR, Wallis N, Armstrong G, et al. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br J Clin Pharmacol 1998; 46 (2): 133–7.
Hawkey C, Kahan A, Steinbruck K, International Meloxicam Large-Scale International Study Safety Assessment (MELISSA) Study Group, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37 (9): 937–45.
Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-Inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37 (9): 946–51.
Bayerl C, Pagung R, Jung EG. Meloxicam in acute UV dermatitis: a pilot study. Photodermatol Photoimmunol Photomed 1998; 14 (5–6): 167–9.
Lopez-Garcia JA, Laird JM. Central antinociceptive effects of meloxicam on rat spinal cord in vitro. Neuroreport 1998; 9 (4): 647–51.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Davies, N.M., Skjodt, N.M. Clinical Pharmacokinetics of Meloxicam. Clin Pharmacokinet 36, 115–126 (1999). https://doi.org/10.2165/00003088-199936020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199936020-00003